Since our data suggests that modest EGFR blockade modifies muscle phenotype, lower, and hence more tolerable, doses than those used in cancer treatment regimens (which aim for total downstream signaling blockade32,33) may be efficacious in COPD patients. Here, EGFR is linked to chronic obstructive pulmonary disease.